SCHEMBL165776

SCHEMBL165776

N#Cc1cc(F)c(Cl)nc1Cl

nearest known ligand 0.69

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
KHK P50053 1/20 0.69
SMN1; SMN2 Q16637 1/20 0.46
ALDH1A1 P00352 3/20 0.44
CYP11B2 P19099 5/20 0.42
KEAP1 Q14145 1/20 0.42
NFE2L2 Q16236 1/20 0.42
NPSR1 Q6W5P4 2/20 0.42
CYP1A2 P05177 1/20 0.42
CYP2C9 P11712 1/20 0.42
CYP2C19 P33261 1/20 0.42
TRPV4 Q9HBA0 2/20 0.42
TDP1 Q9NUW8 1/20 0.38
CYP11B1 P15538 4/20 0.38
KDM4E B2RXH2 1/20 0.36
GAA P10253 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29448447 1.00 KHK (0.69) KHKSMN1; SMN2ALDH1A1CYP11B2KEAP1
SCHEMBL29448448 1.00 KHK (0.69) KHKSMN1; SMN2ALDH1A1CYP11B2KEAP1
SCHEMBL31633214 0.85 KHK (0.67) KHKSMN1; SMN2ALDH1A1CYP11B2NPSR1
SCHEMBL14332441 0.85 KHK (0.67) KHKSMN1; SMN2ALDH1A1CYP11B2NPSR1
SCHEMBL566209 0.84 KHK (0.57) KHKSMN1; SMN2ALDH1A1NPSR1CYP1A2
SCHEMBL19220966 0.83 KHK (0.65) KHKSMN1; SMN2ALDH1A1CYP11B2NPSR1
SCHEMBL23860801 0.82 KHK (0.73) KHKSMN1; SMN2ALDH1A1CYP11B2KEAP1
SCHEMBL33526529 0.82 KHK (0.53) KHKSMN1; SMN2ALDH1A1CYP11B2KEAP1
SCHEMBL6050497 0.82 KHK (0.62) KHKSMN1; SMN2ALDH1A1CYP11B2NPSR1
SCHEMBL9967116 0.82 KHK (1.00) KHKSMN1; SMN2ALDH1A1CYP11B2NPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 675 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-114990898-A High-elasticity wear-resistant fabric and preparation method thereof 王正文 2022-09-02 CN claimed
US-7414136-B2 Method for producing 3-substituted 2-chloro-5-fluoro-pyridine or its salt ASAHI GLASS COMPANY, LIMITED (JP) 2008-08-19 US claimed
US-6441182-B1 Method for the production of 2,6-dichloro-5-fluoro-nicotinic acid and coarse and particularly pure 2,6-dichloro-5-fluoro-nicotinic acid BAYER AKTIENGESELLSCHAFT (DE) 2002-08-27 US claimed
EP-1192138-A1 METHOD FOR THE PRODUCTION OF 2,6-DICHLORO-5-FLUORO-NICOTINIC ACID AND COARSE AND PARTICULARLY PURE 2,6-DICHLORO-5-FLUORO-NICOTINIC ACID Bayer Aktiengesellschaft (DE) 2002-04-03 EP claimed
US-6197964-B1 CHLORINATION USING BASIC CATALYST; DESALTING, HYDROLYSIS BAYER AKTIENGESELLSCHAFT (DE) 2001-03-06 US claimed
WO-2000076978-A1 METHOD FOR THE PRODUCTION OF 2,6-DICHLORO-5-FLUORO-NICOTINIC ACID AND COARSE AND PARTICULARLY PURE 2,6-DICHLORO-5-FLUORO-NICOTINIC ACID BAYER AKTIENGESELLSCHAFT (DE) 2000-12-21 WO claimed
EP-0973745-A1 METHOD FOR THE PRODUCTION OF 2,6-DICHLORO-5-FLUORONICOTINONITRILE AND THE CHEMICAL COMPOUND 3-CYANO-2-HYDROXY-5-FLUOROPYRIDE-6-ONE-MONOSODIUM SALT AND ITS TAUTOMERS BAYER AG (DE) 2000-01-26 EP claimed
WO-1998043958-A1 METHOD FOR THE PRODUCTION OF 2,6-DICHLORO-5-FLUORONICOTINONITRILE AND THE CHEMICAL COMPOUND 3-CYANO-2-HYDROXY-5-FLUOROPYRIDE-6-ONE-MONOSODIUM SALT AND ITS TAUTOMERS BAYER AKTIENGESELLSCHAFT (DE) 1998-10-08 WO claimed
EP-0333020-A2 Process for the preparation of substituted pyridines ABBOTT LABORATORIES (US) 1989-09-20 EP claimed
JP-1299272-A None JP disclosed
US-20260138991-A1 SEMI-SATURATED BICYCLIC DERIVATIVES AND RELATED USES MOMA THERAPEUTICS INC (US) 2026-05-21 US disclosed
US-12630549-B2 Pyrazoleamide derivatives HOFFMANN-LA ROCHE INC. (US) 2026-05-19 US disclosed
US-12583852-B2 Heterocycle derivative JW PHARMACEUTICAL CORPORATION (KR) 2026-03-24 US disclosed
EP-4705298-A2 SEMI-SATURATED BICYCLIC DERIVATIVES AND RELATED USES Moma Therapeutics, Inc. (US) 2026-03-11 EP disclosed
EP-0132845-B1 NOVEL 1,8-NAPHTHYRIDINE DERIVATIVES, AND PROCESS FOR PREPARATION THEREOF Dainippon Pharmaceutical Co., Ltd. (JP) 1988-04-13 EP disclosed
US-4649144-A Antibacterial 7-(3-amino-1-pyrrolidinyl)-1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-1,8-naphthyridine-3-carboxylic acid derivatives DAINIPPON PHARMACEUTICAL CO., LTD. (JP) 1987-03-10 US disclosed
US-4617308-A 7-substituted amino-1-aryl-6,8-difluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acids and derivatives thereof as antibacterial agents WARNER-LAMBERT COMPANY (US) 1986-10-14 US disclosed
EP-0187376-A2 6,7-Disubstituted 1-cyclopropyl-1,4-dihydro-4-oxo-1,8-naphthyridine-3-carboxylic acids BAYER AG (DE) 1986-07-16 EP disclosed
EP-0160578-A1 1,8-Naphthyridine derivatives DAIICHI SEIYAKU CO., LTD. (JP) 1985-11-06 EP disclosed
EP-0132845-A2 Novel 1,8-Naphthyridine derivatives, and process for preparation thereof Dainippon Pharmaceutical Co., Ltd. (JP) 1985-02-13 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260138991-A1 SEMI-SATURATED BICYCLIC DERIVATIVES AND RELATED USES POLA1, SUB1, CTDSP1 KHK 1388/4885SMN1; SMN2 836/4885ALDH1A1 840/4885
US-12583852-B2 Heterocycle derivative AR, SRD5A1, NR5A1 KHK 3410/4885SMN1; SMN2 4493/4885ALDH1A1 1733/4885
US-12630549-B2 Pyrazoleamide derivatives CYP11B2, CYP11B1, ADRA1B KHK 1298/4885SMN1; SMN2 2210/4885ALDH1A1 439/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.